Spur Therapeutics

Spur Therapeutics is a clinical-stage biotechnology company developing adeno-associated virus-based gene therapies for serious chronic diseases.

Its lead programme is a Phase I/II gene therapy for Gaucher disease type 1, a rare lysosomal storage disorder.

Further pipeline candidates target GBA1 Parkinson's disease and adrenomyeloneuropathy, with a research strategy extending into more prevalent neurological and cardiovascular conditions.

The company optimises vector, transgene, and delivery components to achieve therapeutic effect at lower doses.